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Abstract
Nutrition is apparently a major risk factor for the
development and progression of prostate cancer.
Based on experimental studies and epidemiologic
data mainly from case-control studies or cohort
studies, there is strong evidence that reduction of the
total energy consumption, a diet comprising less
than 30% fat, and increased intake of phytoestro-
gens, vitamins D and E and selenium could yield a
decreased prostate cancer incidence. Furthermore,
some of these measures appear to have antitumoral
capacity even in the presence of the disease. These
observations have provided a rationale to forward
large prospective trials on dietary interventions to
prove the efficacy of the concept and further delin-
eate the correlation between nutritional compounds
and prostate cancer risk. These chemoprevention 
trials are either aiming a reduction prostate cancer
incidence or a decrease in tumor progression. De-
pending on the study design, large numbers of indi-
viduals need to be enrolled and long follow-up inter-
vals are required thus making such trials highly
complex and cost-intensive. However, regarding the
potential relevance of chemoprevention on public
health, further efforts to identify nutritional factors
affecting prostate cancer growth are warranted.
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Prostate Cancer
Introduction
Epidemiologic studies have demonstrated that the
incidence of clinically overt prostate cancer is about 10
times higher in White US American men as compared
to Japanese men with a comparable socioeconomic
background [1, 2]. Furthermore, migration studies
showed that the low prostate cancer incidence in Japan-
ese immigrants in the US rose about 3 times within one
generation. Also in Europe there is a significant differ-
ence in prostate cancer incidence from 11.8/100,000
male population in Portugal to 50.2/100,000 males in
Sweden.
Although prostate cancer is one of the most common
cancers in western Countries, its etiology is mostly
unknown. However, aside of age and ethnicity, several
environmental factors, including diet, have been iden-
tified in epidemiological studies, although these find-
ings have not been completely consistent [3–5]. So far,
several nutritional compounds have been suggested to
influence prostate cancer (table 1). Through the past
decade the understanding of the molecular mecha-
nisms potentially underlying these effects have been
identified thus now providing the basis for interven-
tional studies.
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Table 1. Nutritional compounds potentially involved in the
development of prostate cancer
Phytoestrogens
Antioxidants (carotenoids, vitamins A, C, D, E)
Selenium
Fat/total energy uptake
2 Urol Int 2001;67:1–11 Schmitz-Dräger/Eichholzer/Beiche/
Ebert
Phytoestrogens
Testosterone is known to play a crucial role in the
development and progression of benign and malignant
prostatic disease. Although it remains a matter of dis-
cussion if testosterone serum levels are correlated with
the incidence of prostate cancer [6–8], several observa-
tions suggest that free testosterone might be one of the
factors inducing and stimulating prostate cancer. Phy-
toestrogens are known to be strong inhibitors of 5--
reductase thus potentially counteracting testosterone-
mediated stimulation of prostatic growth [9, 10].
There is some epidemiologic evidence that phyto-
estrogens may influence progression of benign and
malignant prostatic disease [5, 11, 12]. Diets in areas
with a low prostate cancer incidence (far-east Asia,
southern Europe) are rich in fibers and vegetables con-
taining high amounts of isoflavonoids, flavonoids and
lignans, the most important categories of phytoestro-
gens. While high concentration of flavonoids and
isoflavonoids, e.g. daidzein or genistein, are detected in
vegetables (e.g. soy) and fruits, lignans can also be
found at high concentrations in linseeds, grains and
cereals. Phytoestrogens may influence growth and pro-
liferation of prostate cells through different mecha-
nisms (table 2). As expected, serum levels or urinary
concentrations of phytoestrogen metabolites are much
higher in men from areas with low prostate cancer inci-
dence as compared to men from western countries
[11–13].
Despite experimental and epidemiologic evidence
from ecological studies on the beneficial effects of phy-
toestrogens, only few data from case-control and cohort
studies have been published so far. Two case-control
studies report a significant inverse correlation between
phytoestrogen intake and prostate cancer risk [14, 15].
These observations are further supported by the sum-
marized data from three case-control studies including
617 prostate cancer cases from Canada [16]. The intake
of green vegetables, beans, lentils, nuts and cruciferous
vegetables was inversely correlated with the incidence
of prostate cancer.
Similar results were obtained in two cohort studies
from the US, both showing significant beneficial effects
of soybean product consumption on prostate cancer
risk [17, 18]. However, despite these encouraging data,
the assessment of dietary phytoestrogen consumption
is highly complex and the results of these trials may be
confounded by multiple parameters [19]. Therefore,
further assessment of this topic is required.
Lycopene
Lycopene is a carotenoid that is present in tomatoes,
processed tomato products and several fruits. It is one
of the most potent antioxidants among dietary
carotenoids. Dietary intake of tomatoes and tomato
products has been shown to be associated with a
decreased risk of chronic diseases [20]. Although the
antioxidant properties of lycopene are thought to be
primarily responsible for its effects, evidence is accu-
mulating that other mechanisms may also be involved.
The effects of lycopene on prostate cancer have been
extensively addressed in a variety of studies. While
case-control studies by Le Marchand et al. [21], Key et
al. [22] and Hayes et al. [23] showed no differences
between those individuals on a lycopene-rich diet and
the controls, the trials by Norrish et al. [24] and Tzo-
nou et al. [25] yielded a decreased risk of developing
prostate cancer for individuals consuming high
amounts of tomatoes or having a lycopene-rich diet
reaching significance only in the latter trial (table 3).
Furthermore, the impact of lycopene on prostate
cancer risk has also been studied in several cohort stud-
ies [26–31] (table 3). All trials studying the effects of
tomato-rich diets showed a significant decrease of the
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w Table 2. Putative mechanisms of phytoestrogen action onprostate cells
Increase of SHBG serum concentration and subsequent 
decrease of free testosterone through binding to liver estrogen
receptors
Decrease of DNA synthesis through inhibition of tyrosine
kinase and topoisomerase
Decrease of the effects of free radicals through antioxidant
properties
Inhibition of cytochrome P450 activation
Neoangiogenesis inhibition
Inhibition of intraprostatic testosterone metabolism through
inhibition of 5-reductase and aromatase
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3Urol Int 2001;67:1–11Nutrition and Prostate Cancer
prostate cancer risk in individuals with a high con-
sumption of tomatoes or tomato products [26, 28, 30].
However, it remains unclear if these beneficial effects
are related to lycopene intake or rather to the multiple
other nutritional compounds in tomatoes.
In three other trials, lycopene serum or plasma lev-
els were studied [27, 29, 31]. While Nomura et al. [29]
did not find a difference between the study groups,
Gann et al. [31] showed a correlation with a significant
decrease of the prostate cancer risk in the group with
high lycopene plasma levels. A similar decrease was
also seen by Hsing et al. [27], however, because of the
small number of prostate cancer cases (n = 103), this
observation was not significant.
In a recent review on 72 studies concerning the
impact of tomatoes and tomato-based products on the
incidence of various cancers, Giovannucci [32] identi-
fied 35 trials reporting a significant inverse relation-
ship. The evidence for a benefit was strongest for can-
cers of the prostate, lung and stomach. Moreover, no
study indicated that higher tomato consumption or
lycopene blood levels statistically significantly in-
creased the risk of cancer of any site.
Vitamins
From epidemiologic evaluations there is a great
body of evidence of an inverse correlation between the
intake of vitamins and the incidence of different types
of cancer. These observations are further supported by
results of experimental trials. Specifically with regard
to the development of prostate cancer, vitamins A, C,
D and E have been suggested to be of relevance.
The molecular pathways through which vitamins
may act are severalfold. Neutralization of the oxidative
capacity of free radicals in the tissue appears to be a
major way of action for several vitamins [33]. Further-
more, stimulation of the immune system and its puta-
tive antitumoral actions has been shown to be mediat-
ed through vitamins. Retinoids and vitamin A are
known to be strong inducers of cellular differentiation.
Within this context the loss of intercellular interaction,
another aspect of dedifferentiation, can be restored
under the influence of vitamins. Apart from these indi-
rect actions, direct antiproliferative effects of several
vitamins in vitro and in vivo have been reported
[33–38].
Total Vitamin A (-Carotene and Retinol)
There is some experimental evidence that the provi-
tamins or vitamin A may influence the development
and progression of prostate cancer. Williams et al. [38]
demonstrated an in vitro down-regulation of the pro-
liferation of prostate cancer cells in the presence of -
carotene. Further investigation suggests a metabolic
conversion of -carotene to retinol by the prostate
tumor cells. This observation supports the results of a
Table 3. Summary of trials investigating the influence of lycopene and tomatoes/ 
tomato products on the incidence of prostate cancer
Reference Cases Measure Ass. RR/OR (95% CI)1
Case-control trials
Le Marchand (1991) [21] 452 Diet NS 0.9 70 years
NS 1.1 70 years
Key (1997) [22] 328 Diet NS 0.99 (0.68–1.45)
Tzonou (1997) [25] 320 Tomatoes  0.70
Hayes (1999) [23] 932 Diet NS
Norrish (2000) [24] 317 Diet NS 0.76 (0.50–1.17)
Cohort studies or nested case-control studies
Mills (1989) [26] 180 Tomatoes  0.60 (0.37–0.97)
Hsing (1990) [27] 103 Serum NS 0.50 (0.20–1.29)
Giovannucci (1995) [28] 773 Tomato products  0.65 (0.44–0.95)
Nomura (1997) [29] 142 Serum NS 1.1  (0.5–2.2)
Cerhan (1997) [30]            1,050 Tomatoes  0.5  (0.3–0.9)
Gann (1998) [31] 578 Plasma  0.56 (0.34–0.92)
NS = Statistically not significant; = statistically significant inverse association.
1 Comparing extreme categories, low = reference.
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trolled -carotene intake could be hazardous. Howev-
er, so far, it appears that supplementation of -carotene
could be beneficial in a distinct group of men with low
-carotene plasma levels.
Vitamin C
The influence of vitamin C on prostate cancer has
been studied in a number of case-control studies and
cohort trials [49–57] (table 4). In the majority of these
studies no evidence of an inverse association between
vitamin C intake or vitamin C plasma concentrations
on the incidence or mortality of prostate cancer was
noted. A borderline significant inverse association was
observed with daily supplemented use only in the case-
control study by Kristal et al. [57]. It was suggested that
higher than dietary amounts of vitamin C might be nec-
essary for a protective effect. Although the results of
prospective interventional trials are not yet available, it
appears unlikely that vitamin C may play a major role
in prostate cancer prevention.
Vitamin D
Vitamin D plays a crucial role in osseous metabo-
lism and vitamin D deficiency or vitamin D receptor
disorders are correlated with osteomalacia. Further-
more, it has been speculated that decreased vitamin D
serum levels could be responsible for the increased risk
in Black US citizens developing prostate cancer. Peehl
et al. [35, 36] studied the antiproliferative effects of vit-
amin D3 in primary cultures of prostatic tissues derived
from prostate cancer patients. The antiproliferative
effects of vitamin D3 were more pronounced in
prostate cancer cells as compared to prostate fibro-
blasts. A decreased expression of vitamin D receptors
in fibroblasts was suggested to be responsible for this
observation. Further investigation of the mechanism
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Table 4. Summary of trials investigating the influence of vitamin C on the incidence
or mortality of prostate cancer
Reference Cases Measure Ass. RR/OR (95% CI)1
Case-control
Vlajinac (1997) [56] 101 Diet NS 0.90 (0.48–1.69)
Deneo-Pelegrini (1997) [52] 175 Diet  0.4 (0.2–0.8)
Kristal (1999) [57] 697 Suppl. NS 0.77 (0.57–1.04)
Cohort studies
Daviglus (1996) [50] 132 Diet NS 1.03 (0.59–1.6)
Eichholzer (1999) [54] 30 Plasma NS 0.93 (0.31–2.78)2
NS = Statistically not significant;  = statistically significant inverse association.
1Comparing extreme categories, low = reference; 2high = reference.
case-control study in Japan which showed that con-
sumption of vegetables containing 600 g carotin/
100 g was associated with a decreased prostate cancer
risk [39, 40]. An inverse correlation between higher
carotene intake and prostate cancer risk was also
observed in a case-control study in England [19]. These
findings contrast to the results obtained in a recent
case-control study by Norrish et al. [24] and in the
Lutheran Brotherhood Cohort Study [41].
Most notable, the effects of -carotene on prostate
cancer risk have also been addressed in large interven-
tional studies. The CARET trial (30 mg -carotene/
day) and the Physicians’ Health Study (PHS) I (50 mg
-carotene every second day) could not demonstrate a
beneficial effect of -carotene on prostate cancer inci-
dence [42–44]. However, in the PHS I trial those indi-
viduals with initial low plasma levels of -carotene had
a statistically significant 32% risk reduction after sub-
sequent -carotene supplementation as compared to
those individuals not receiving -carotene [43]. This
contrast to a nonsignificant 33% increase in prostate
cancer incidence in the individuals with high pre-study
-carotene plasma levels.
These findings could explain the observations made
in the ATBC interventional trial including 29,133 male
smokers aged 50–69 years, where the treatment group
received 20 mg -carotene/day alone or in combination
with -tocopherol (50 mg) [45–48]. In this group an
increased incidence (23%) and mortality (15%) from
prostate cancer was observed. Since no pre-study exam-
ination of the plasma levels was performed, a possible
interaction of low or high -carotene levels could not be
disclosed.
In summary, the effects of -carotene or total vita-
min A on the development of prostate cancer remain
inconclusive. There is even some evidence that uncon-
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5Urol Int 2001;67:1–11Nutrition and Prostate Cancer
underlying the antiproliferative effects showed that
growth inhibition was mediated both by androgen-
dependent and androgen-independent pathways [37].
The relation between the intake of dairy products
and prostate cancer risk has been investigated in a pop-
ulation-based case-control study by Chan et al. [58].
The investigation of 526 cases and 536 controls showed
calcium intake to be an independent predictor of
prostate cancer, and specifically for metastatic tumors.
Since calcium consumption is supposed to lower vita-
min D serum levels, the correlation between vitamin D
metabolite serum levels and prostate cancer was stud-
ied in a nested case-control study in a Japanese-Amer-
ican population including 136 cases and 136 matched
controls [61]. No difference between vitamin D serum
levels in the two groups was observed. However, indi-
viduals with low vitamin D serum levels were under-
represented which may hide an existing difference
(table 5).
The investigation of stored sera collected from over
250,000 individuals through the years 1964–1971
showed significantly lower vitamin D serum levels in
older patients (57 years) with prostate cancer as com-
pared to controls without prostate cancer [62]. Similar-
ly, Ahonen et al. [60] reported a correlation between
low vitamin D serum levels and subsequent develop-
ment of prostate cancer in a Finnish study including
19,000 healthy men. However, in this trial low vitamin
D serum levels were specifically linked to aggressive
tumors in younger patients.
Other studies aiming at the relation between vita-
min D receptor polymorphism and prostate cancer risk
yielded controversial results. While a heterozygosity or
homozygosity for the absence of the Bsm I restriction
site was associated with significant decrease of the
prostate cancer risk in a Japanese population [65], this
finding was not confirmed in a case-control study nest-
ed in the Physicians’ Health Study [66].
So far, only phase I/II trials on a therapeutical use of
vitamin D have been published. Gross et al. [67]
demonstrated a significant decrease of serum PSA in 6
of 7 patients with early recurrent prostate cancer
receiving 0.5–2.5 g vitamin D3/day for 6–15 months.
Van Veldhuizen et al. [68] investigated vitamin D
replacement therapy in patients with hormone-refrac-
tory metastatic prostate cancer. Four of the 16 patients
had improvements in pain scores and 6 patients had
improved muscle strength measurements. Notably, 7 of
the 16 patients had decreased baseline vitamin D lev-
els.
In summary, the role of vitamin D deficiency in the
development of prostate cancer remains controversial.
Despite the influence of high-dose vitamin D treatment
on serum PSA, more detailed analyses are required to
accept this approach as a viable therapeutic option.
Vitamine E (-Tocopherol)
Vitamin E is a potent intracellular antioxidant with
demonstrable antitumoral properties in several cancer
models including sarcomas and gastrointestinal tumors
[69–71]. It has been hypothesized that the antioxidant
properties of vitamin E may reduce the dietary fat-
induced oxidative stress and thus subsequently affect
tumor cell growth.
Based on these investigations and further epidemio-
logic evidence that vitamin E could also have a pre-
ventive effect in prostate cancer, this question has been
addressed in more detail in a variety of epidemiologi-
Table 5. Summary of trials investigating the influence of serum vitamin D and 
calcium intake on the incidence of prostate cancer
Reference Cases Measure Ass. RR/OR (95% CI)1
Case-control
Vlajinac (1997) [56] 101 Dietary calcium  0.37 (0.14–0.99)
Chan (1998) [58, 59] 526 Dietary calcium  1.9 (1.2–3.0)
Kristal (1999) [57] 697 Suppl. dietary calcium NS 1.04 (0.61–1.78)
Ahonen (2000) [60] 149 Serum (vitamin D)  1.7
Cohort studies or nested case-control studies
Nomura (1988) [61] 136 Serum NS 1.0 (0.5–2.1)
Giovannucci (1998) [63] 423 Diet (calcium intake)  2.97 (1.6–5.5)
Schuurman (1999) [64] 642 Diet (calcium intake) NS n.r.
NS = Statistically not significant;  = Statistically significant inverse association; 
 = statistically significant direct association.
1 Comparing extreme categories, low = reference; n.r. = not reported.
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cal studies (table 6). However, although several case-
control studies provided some evidence for a decreased
incidence of prostate cancer in populations consuming
a vitamin E-rich diet, this finding was not confirmed in
subsequent cohort studies [5, 45–48].
Stratification for several risk factors in the Basel
Cohort Study, however, showed that smokers with low
vitamin E plasma levels had a significantly increased
risk of prostate cancer mortality [54]. Reanalysis of the
respective data from several other studies were mostly
in concordance with this finding (table 7). In the ATBC
interventional trial this hypothesis could be confirmed
[45, 47]. Subjects receiving -tocopherol (50 mg daily)
for 5–8 years had a 32% decrease in the incidence and
a 41% reduction in mortality from prostate cancer.
In summary, results of epidemiological studies do
not support a general protective effect of vitamin E
against prostate cancer. However, results of four dis-
tinct populations, the US physicians’ study, the Finnish
ATBC trial, the Swiss Basel Study and the US health
professionals’ blood investigations, suggest that vita-
min E may provide benefits against advanced prostate
cancer or prostate cancer mortality among smokers or
recent ex-smokers, but not among nonsmokers [31,
45–48, 54, 74].
Selenium
The inhibitory effect of selenomethionine, the pre-
dominant from of selenium in dietary supplements on
the growth of prostate cancer cells and other tumor cell
lines in vitro, has recently been studied by Redman et
al. [75]. They found tumor cells to be approximately
Table 7. Summary of trials investigating the influence of vitamin E on the incidence
and mortality of prostate cancer in smokers
Reference Cases Measure Ass. RR/OR (95% CI)1
Cohort studies or nested case-control studies
Knekt (1988) [73] 1152 Serum NS 0.74 (0.44–1.26)
Chan (1999) [74] 55 Suppl.  0.47 (0.24–0.92)
Gann (1999) [31] 578 Plasma  0.51 (0.26–0.98)
Eichholzer (1999) [54] 30 Plasma  3.26 (1.27–8.35)2
Interventional studies
ATBC [45–48] 62 50 mg  0.59 (0.35–0.99)
NS = Statistically not significant; = statistically significant inverse association.
1 Comparing extreme categories, low = reference; 2 High = reference.
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Reference Cases Measure Ass. RR/OR (95% CI)1
Case-control
Rohan (1995) [53] 207 Diet NS n.r.
Andersson (1996) [72] 526 Diet NS 0.91 (0.64–1.28)
Vlajinac (1997) [56] 101 Diet  0.15 (0.05–0.53)
Deneo-Pelegrini (1999) [52] 175 Diet  ptrend 0.6 (0.3–1.1)
Hayes (1999) [23] 932 Diet NS n.r.2
Tzonou (1999) [25] 320 Diet  0.53 (0.30–0.94)
Kristal (1999) [57] 697 Suppl. NS 0.76 (0.54–1.08)
Cohort studies or nested case-control studies
Knekt (1988) [73] 26 Serum NS 0.42 (0.10–1.71)
Hsing (1990) [41] 103 Serum NS 1.00 (0.37–2.68)
Nomura (1997) [29] 142 Serum NS 0.9 (0.7–2.9)
Chan (1999/2000) [58, 59] 1,896 Suppl. NS 1.07 (0.95–1.20)
Gann (1999) [31] 578 Plasma NS 0.64 (0.38–1.07)
Eichholzer (1999) [54] 30 Plasma NS 0.76 (0.25–2.37)2
NS = Statistically not significant;  = statistically significant inverse association.
1 Comparing extreme categories, low = reference; 2high = reference; n.r. = not reported.
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7Urol Int 2001;67:1–11Nutrition and Prostate Cancer
1,000 times more sensitive as compared to normal
diploid fibroblasts.
These observations match with data from a longitu-
dinal case-control study on 111 subjects developing
cancer within 5 years after obtaining blood samples for
determination of serum selenium levels and compared
the results with the levels of 210 control individuals not
developing cancer within the same period [76]. The
mean selenium levels of the cancer patients was signif-
icantly lower as compared with the controls. A similar
study design was chosen in a prospective case-control
study by Criqui et al. [77]. Baseline levels of plasma
selenium, retinol and retinol-binding protein were
compared in 136 case patients who subsequently died
from cancer and 238 matched controls. Serum seleni-
um was lower in case patients with gastrointestinal or
prostate cancer, however, without reaching signifi-
cance.
Hardell et al. [78] reported on a case-control study
comparing selenium plasma levels from 164 patients
with prostate cancer with 152 patients with benign pro-
static hyperplasia. In those patients not taking supple-
mentary selenium, the selenium levels were signifi-
cantly lower in the cancer patients as compared to the
controls. Yoshizawa et al. [79] conducted a nested case-
control study within a large cohort study including
51,529 health professionals. Selenium levels were
determined in toenail clippings. After controlling for
several potentially interfering factors, higher selenium
intake was found to be associated with a reduced risk
for advanced prostate cancer.
For those patients enrolled in the ATBC study, base-
line levels for several parameters were obtained [48].
No significant differences were reported for the inci-
dence of prostate cancer and serum selenium levels. In
an another interventional trial, Combs et al. [80] ran-
domized 1,312 patients with a history of basal/squa-
mous cell carcinoma in a double-blind fashion to either
receive 200 g selenium/day or placebo. While recur-
rence of skin cancer was not significantly reduced, total
mortality and cancer mortality from all cancers, and in
particular incidence and mortality from prostate can-
cer (secondary endpoints of the trial), were significant-
ly reduced [81].
Dietary Fat
A high-fat diet has frequently been associated with
an increased risk of prostate cancer. This aspect has
been studied in in-vivo experiments where the growth
of LNCaP cells in nude mice was investigated. Tumor
Table 8. Summary of trials investigating the influence of dietary fat on the incidence
of prostate cancer
Reference Cases Ass. RR/OR (95% CI)
Case-control studies
West (1991) [51] 679  2.9 (1.08–8.4)
Ghadirian (1996) [83] 232 NS n.r.
Vlajinac (1997) [56] 101  3.6 (1.0–12.8)
Meyer (1997) [84–86] 215  2.67 (??)
Lee (1998) [87] 133  3.6 (1.8–7.2)
Deneo-Pelegrini (1999) [52] 175 Trend 1.8 (0.9–3.4)
Tzonou (1999) [25] 320  n.r.
Ramon (2000) [55] 217  2.0 (1.2–3.2)
Cohort studies or nested case-control studies
Severson (1989) [17] 174 NS 0.91 (0.64–1.28)
Veierod (1997) [88] 72 NS 1.3 (0.6–2.8)
LeMarchand (1994) [89] 198  1.6 (1.0–2.4)
Hayes (1999) [23] 932
Total PCA NS/2 1.1–2.1
Advanced PCA /2 2.2–4.2
Schuurman (1999) [90] 642 NS 1.1
NS = Statistically not significant;  = statistically significant direct association.
1 Comparing extreme categories, low = reference; n.r. = not reported.
2 White/Black US citizens.
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growth and serum PSA were significantly decreased in
those animals receiving a low-fat diet as compared to
control mice receiving an isocaloric high-fat diet [5].
Several aspects of increased fat intake, i.e. high
serum cholesterol, total fat intake, the intake of satu-
rated or unsaturated fatty acids or animal fat consump-
tion have been studied in a variety of case-control or
cohort studies (table 8). In a recent review addressing
this topic, 11 out of 14 case-control trials yielded a sig-
nificant correlation between fat consumption and
prostate cancer risk [5]. Furthermore, 4 of the 5 cohort
studies cited including nearly 100,000 individuals re-
ported a relative risk ranging from 1.8 to 2.4 for people
with high-fat intake. Even a correlation between fat
consumption and high-grade/high-stage prostate cancer
and prostate cancer mortality has been suggested by
several studies [5, 82]. Meyer et al. [84–86] showed that
a high intake of saturated fatty acids in patients with
prostate cancer was significantly associated with tumor
progression and mortality. In contrast to most earlier
studies, these data were adjusted for total calorie intake.
These observations are further supported by studies
reporting a correlation between overweight (body mass
index) and the prostate cancer risk [5, 30, 91, 92]. In
contrast to the obvious-tumor-promoting effects of sat-
urated fats especially from animal sources, the intake of
fat derived from plants or -3 fatty acid appears not
relate to an increased risk developing prostate cancer
[5, 93, 94].
Conclusions
Large autopsy studies suggest that the incidence
latent prostate cancer is similar worldwide. This obser-
vation contrasts to the regionally different incidence of
overt or clinically relevant tumors. Therefore, already
a long time ago an environmental influence on the pro-
gression of microscopic to clinically relevant prostate
cancer was postulated. This hypothesis was supported
by migration studies demonstrating the increase of
prostate cancer incidence in populations moving from
areas with a low incidence in the Far East to areas with
high incidence in the US [1, 2].
Throughout the last two decades a significant num-
ber of studies on the impact of nutritional compounds
on the development but also on the course of disease of
prostate cancer have been published. Considering the
general question regarding an effect of nutrition on
prostate cancer there is – despite several contradictory
reports – increasing evidence supporting this hypothe-
sis [95]. However, when it comes to more detailed ques-
tions aiming at the nature of relevant nutritional com-
pounds, instead of clear conclusions more and more
open questions remain.
These contradictory observations are better under-
stood in the light of the complexity of the problem. 
So far, multiple factors potentially influencing the
results of the respective trials have been identified
(table 9).
Hypotheses of actual trials are frequently based
upon results obtained in studies of questionable quali-
ty. Most results discussed in numerous review articles
on this topic have been obtained by case-control stud-
ies. However, the validity of this type of trial is limited
since selection bias is immanent and may be responsi-
ble for conflicting results [96]. In contrast, the impact
of cohort studies is certainly superior, but high costs
and long follow-up intervals required in general repre-
sent significant obstacles to launch this type of study.
The most valuable information can be obtained
through interventional trials, however until today only
very few trials of this type have been generated to study
the role of nutrition on prostate cancer [42–48, 97].
The validity of questionnaires is another problem
that may distort the results of those trials relaying on
self-reports of individuals. An investigation on the reli-
ability of self-reports demonstrated a high level of inac-
curacy specifically if non-life-threatening issues were
assessed [98–100]. This has led to the inclusion of
objective parameters through the analysis of serum, tis-
sue, saliva and toenails in more recent trials [81, 101,
102].
Furthermore, the fact that hereditary factors also
affect the results of epidemiologic studies on prostate
cancer [103] and, furthermore, that data from different
Table 9. Factors influencing the result of trials investigating
the impact of nutrition on prostate cancer
Validity of studies (case-control, cohort studies, interventional 
trials)
Problem of follow-up interval in the interventional and most
cohort studies
Reliability of questionnaires
Hereditary factors
Data from different ethnical populations
Correlation between nutrition and lifestyle
Interaction between several nutritional compounds
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ethnical populations yield different results further
impedes the interpretation of the reports [104]. How-
ever, even within ethnically homogeneous populations,
the correlation between nutrition and life-style may be
confounded by genetic factors. Cross-national (meta)-
analyses could be one option to address this problem
but the quality of the different trials included in this
type of study is hard to control for [105].
Apart from these factors that could be theroretically
taken into account designing a trial on nutrition in
prostate cancer, the interaction between the different
nutritional compounds remains a key problem in pop-
ulation-based trials. Considering the putative benefi-
cial effects of tomatoes and tomato products, it is near-
ly impossible to identify which of the multiple
compounds or which combination of compounds may
be responsible for beneficial effects. And even the
administration of a single compound – e.g. a vitamin –
may be influenced by other interacting nutritional or
lifestyle factors.
However, these problems should not discourage the
scientific community to conduct further well-designed
trials on this import issue but should caution inade-
quate expectations and overinterpretation of the results
of single trials. Today the concept of an impact of nutri-
tion on prostate cancer appears well established but the
details still require further characterization. Primary
and secondary as well as tertiary prevention need to be
addressed [97]. Considering the noninvasiveness of
this approach and the putative benefits, a thorough
investigation of this issue appears worthwhile and cer-
tainly justifies the efforts invested in this topic world-
wide [97, 106, 107].
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